Research programme: small molecule SHIP modulators - Aquinox Pharmaceuticals

Drug Profile

Research programme: small molecule SHIP modulators - Aquinox Pharmaceuticals

Alternative Names: AQX-016A; AQX-100; AQX-100 series; AQX-1000 series; AQX-200 series; AQX-252; AQX-273; AQX-278; AQX-300 series; AQX-356; AQX-MN100; AQX-MN106; AQX-MN278; AQX-SHIP inhibitors; AXQ C5; SHIP1 inhibitors

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Aquinox Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Inositol-1,4,5-trisphosphate 5 phosphatase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Inflammation
  • Research Haematological disorders; Immunological disorders
  • Discontinued Allergic conjunctivitis; Dry eyes

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a preclinical study in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Haematology
  • 04 Jun 2013 Preclinical trials in Haematological malignancies in Canada (unspecified route)
  • 17 Jun 2010 Aquinox completes $US25 million in Series B financing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top